Meeting
2018 Cancer Survivorship Symposium
Successful use of buprenorphine/naloxone to treat opioid addiction after cancer therapy.
Authors
Natalie Moryl
Memorial Sloan Kettering Cancer Center, New York, NY
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Chronic Anticancer Therapy; Late- and Long-term Effects/Comorbitidities; Psychosocial Issues; Risk Assessment
Track
Care Coordination, Cost, and Education,Late- and Long-term Effects/Comorbidities,Health Promotion,Psychosocial Issues,Communication and Transitions,Risk Assessment,Chronic Anti-Cancer Therapy
Sub Track
Long-term Complications/Sequelae of Treatment (Noncancer)
Citation
J Clin Oncol 36, 2018 (suppl 7S; abstr 126)
DOI
10.1200/JCO.2018.36.7_suppl.126
Abstract #
126
Poster Bd #
B17
Abstract Disclosures
Similar Posters
Poster
2017 Palliative and Supportive Care in Oncology Symposium
Methadone as the initial long-acting opioid in children with advanced cancer.
First Author: Kevin Madden
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Efficacy and safety of methadone in the treatment of pain in palliative care patients with cancer: The EQUIMETH2 national, randomized, open, phase III study.
First Author: Philippe Poulain
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Clinical and health care setting of patients admitted at Pain Control Center Hospice of Solofra: A feasibility model of end-of-life care in the Avellino province of Italy.
First Author: Geppino Genua
Poster
2022 ASCO Annual Meeting
Persistent high-risk opioid use in lymphoma survivors following treatment.
First Author: Katherine Ann Stafford